Biomarker ID | 456 |
PMID | 19773444 |
Year | 2009 |
Biomarker | MIC-1 (Macrophage inhibitory cytokine 1) |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Blood |
Subjects | Humans |
Regulation | Downregulated after one round of chemotherapy |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-TAp63 pathway, p73 transcription factor network,p53 signaling pathway,BDNF signaling pathway |
Experiment | Metastatic HRPC patients Pre Vs Post One round of Docetaxel chemotherapy |
Type of Biomarker | Predictive |
Cohort | Plasma/serum samples were collected from a cohort of 43 men with metastatic HRPC (Hormone Refactory Prostate Cancer) treated with chemotherapy |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.02 |
Method Used | ELISA |
Clinical | Yes |
Remarks | Serum/Plasma concentration was used to evaluate status of the biomarker |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | GDF15 |